Optimizing Accelerated TMS for Chronic Pain

This study is testing a new way to treat chronic pain using a device called the MagVenture X100 Pro transcranial magnetic stimulation system. This system delivers a special type of brain stimulation called accelerated intermittent theta burst stimulation (aiTBS). Researchers will personalize where the stimulation is given on your brain to target areas involved in pain. The goal is to see if this treatment is safe and effective in reducing chronic pain. You might be able to join if you are 18 or older, have had chronic pain for at least 12 months, and your pain hasn't improved with at least two different pain medications. The main way they will measure success is by looking at changes in your pain intensity after 3 months.

Study design: This is an interventional study planning to enroll 30 participants. It is not specified if it is randomized or blinded.
What's involved: Not specified in the trial record.
Compensation: Not stated in the trial record.
Follow-up: The primary endpoint measures change in pain intensity at 3 months, suggesting follow-up for at least this duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Optimizing Accelerated TMS for Chronic Pain With Thompson Sampling

Recruiting

PHASE1Ages 18+InterventionalTreatment

University of Minnesota

~30 participants

Updated 2026-03-27 on ClinicalTrials.gov

What's tested:MagVenture X100 Pro transcranial magnetic stimulation system

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Change in pain intensity

Measured over 3 months

Conditions

Chronic Pain

Where it's being run

1 sites across 1 states

Minnesota1

Study leadership

Alexander B Herman, MD, PhD · PRINCIPAL_INVESTIGATOR · University of Minnesota
David Darrow · PRINCIPAL_INVESTIGATOR · University of Minnesota

Who to contact

Matthew Maple

[email protected]

612-946-1424

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Ages 18 years or older

Ability to provide written informed consent

Ability to read and to communicate verbally and in writing in English

Chronic pain persisting for at least 12 months

Pain refractory to oral pain medication (defined as failing at least two different medication classes)

Average pain intensity of ≥5 on the Numerical Rating Scale (NRS) over the past two weeks

Stable pain medication regimen for at least 4 weeks prior to enrollment

Willing and able to attend all study visits and comply with study procedures

Exclusion

Current substance use disorder (except for nicotine or cannabis) as determined by DSM-5 criteria

Active suicidal ideation with intent or plan as determined by the Columbia-Suicide Severity Rating Scale (C-SSRS)

Lifetime history of bipolar disorder, schizophrenia, or other psychotic disorder as determined by medical history

Self-reported unstable medical conditions that would pose increased risks for TMS or MRI

Pregnancy (as determined by urine pregnancy test) or planned pregnancy during the study period

Contraindications to TMS, including:

History of seizure or epilepsy

Metallic implants in the head (excluding dental fillings)

Cardiac pacemaker or other implanted medical devices

History of significant head trauma

History of intracranial surgery

Medication that significantly lowers seizure threshold that cannot be safely held

Contraindications to MRI, including:

Claustrophobia

Metallic implants or devices

Inability to lie flat for the duration of the scan

Current use of high-dose opioids (\>90 morphine milligram equivalents daily)

Participation in another clinical trial of an investigational medication or device within 30 days prior to enrollment

Any condition that, in the investigator\'s opinion, would make it unsafe or difficult for the participant to complete the study

What this trial measures

Change in pain intensity3 months
measured by the Numerical Rating Scale (NRS) from baseline to after completion of the trial (approximately 3 months). For the NRS, the scores range from 0 to 10, where 0 indicates no pain (better outcome) and 10 is the worst pain that the participant can imagine (worse outcome)

Trialytics